Son güncelleme :
19/11/2024
kanser ilaç   Mercaptopurine  
Oral solüsyon / oral çözelti
Farmasötik preparatlar Kararlılığı Karışımlardaki stabilitesi Stabiliteyi etkileyen faktörler Uyumluluk Kaynaklar pdf
   Kimyasal yapı   

Oral solüsyon / oral çözelti
Kaynaklar   Oral solüsyon / oral çözelti   Kaynaklar : Mercaptopurine  
tip yayın
2396 Dergi Aliabadi HM, Romanick M, Desai S, Lavasanifar A.
Effect of buffer and antioxidant on stability of a mercaptopurine suspension
Am J Health-Syst Pharm 2008 ; 65: 441-447.
3244 afiş Sutra C, Guillemot C, Monnier S, Puiset F, Canonge JM.
Stabilité chimique et microbiologique d'une suspension de mercaptopurine à 5 mg/mL.
SFPO Congress Mandelieu, France 2011
3843 Dergi Peacock G.F, Sauvageot J, Hill A, Killian A.
Evaluation of the Stability of Mercaptopurine Suspension Compounded in a Commercial Vehicle and the Determination of an Appropriate Beyond-use Date.
Int J Pharm Compound 2016 ; 20, 1: 81-85
4177 Dergi Polonini H, Loures da Silva S, Fernandes Brandao M.A, Bauters T, De Moerloose B, De Oliveira Ferreira A.
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF PH4.
Int J Pharm Compound 2018 ;22,6:516-526

  Mentions Légales